Sign in
Taking peopleNo phase

Laser surface treatment combined with cross-linking for keratoconus, compared with cross-linking alone

Compares two eye procedures to treat keratoconus in adults.

Key facts

Who runs it
Instituto de Oftalmología Fundación Conde de Valenciana
Where
Mexico1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
PRoTECT: Corneal Wavefront Guided PRK + Epi-off CXL vs. PTK+Epi-off CXL in Keratoconus
Status
Recruiting
People taking part
50 people, planned
Started
1 Sept 2025
Expected to end
30 Dec 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Schwind AMARIS excimer laser
  • Corneal collagen crosslinking epi-off accelerated
Record updated
28 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18-40 years with keratoconus, a condition where the clear front of the eye (cornea) thins and bulges. It compares two laser treatments, each combined with corneal cross-linking.

Age
18-40 years
Sex
All sexes
Disease stage
Keratoconus, ABCD Belin stage I-III. Age 18-25 y: worsening not required. Age 25-35 y: documented worsening (at least 2 protocol criteria) or high-risk signs, such as Kmax > 53 D, strong family history, severe allergy with constant eye rubbing, or over 12 months ΔKmax ≥ 1.0 D, thinnest cornea decrease ≥ 10 µm, or cylinder increase ≥ 1.0 D. Age 35-40 y: clear recent worsening (at least 2 protocol criteria).
Earlier treatment
No prior eye surgery or eye injury. Prior LASIK is allowed if it caused the corneal bulging.
Biomarker or test result
Thinnest corneal thickness ≥ 450 µm before surgery.

Main reasons for not taking part

  • Scars or cloudy areas in the center of the cornea
  • Prior eye surgery or eye injury, except LASIK that caused the bulging
  • Autoimmune disease or uncontrolled diabetes mellitus
  • Pregnancy or breastfeeding
  • Contact lens wear within 2 weeks before the first check

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Age 18-40 years
  • Diagnosis of keratoconus, ABCD Belin stage I-III at baseline
  • Minimum (thinnest) corneal pachymetry ≥ 450 µm pre-op
  • Written informed consent
  • Age-stratified progression requirements:
  • 18-25 y: keratoconus stage I-III (progression not mandatory)
  • 25-35 y: documented progression (meet ≥ 2 Table-1 criteria below) or, if recent documentation is absent, high-risk features for future progression: Kmax > 53 D, strong family history, severe atopy with persistent eye rubbing, or any of the following over 12 months: ΔKmax ≥ 1.0 D, thinnest pachymetry decrease ≥ 10 µm, or increase in manifest cylinder ≥ 1.0 D
  • 35-40 y: clear, unequivocal recent progression (meet ≥ 2 Table-1 criteria); late-onset documented progression may be considered

Who cannot take part

  • Prior ocular surgery or trauma (exception: prior LASIK if it is the cause of post-surgical ectasia, per protocol text)
  • Contact lens wear within 2 weeks before baseline evaluation
  • Autoimmune disease or uncontrolled diabetes mellitus
  • Central corneal scars or opacities
  • Pregnancy or lactation

This trial is currently available in Mexico.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Keratoconus causes irregular astigmatism and reduced vision. Epi-off corneal crosslinking (CXL) stabilizes the cornea but often leaves higher-order aberrations uncorrected. This randomized, parallel-group trial compares corneal wavefront guided photorefractive keratectomy (corneal wavefront guided PRK, 50 µm therapeutic ablation) combined with accelerated epi-off CXL versus epi-off CXL with epithelial removal by phototherapeutic keratectomy (PTK) using a Schwind AMARIS excimer laser, in adults with keratoconus. The primary endpoint is change in best-corrected distance visual acuity (logMAR) at 12 months. Key secondary endpoints include Kmax, corneal higher-order aberrations, manifest refraction, Scheimpflug densitometry (haze) and Fantes grade, Corvis ST biomechanics, NEI VFQ-25, and endothelial cell density by non-contact specular microscopy at 1, 3, 6 and 12 months.

The 2 groups in the trial

  • Corneal Wavefront Guided PRK + CXLTreatment being tested

    Corneal wavefront guided therapeutic PRK (50 µm) with Schwind AMARIS, followed by accelerated epi-off CXL. Intensity: 30 mW/cm² (pulsed 1 s on / 1 s off; 50% duty cycle). Total energy (fluence): 5.4 J/cm². Total time (elapsed): 6 minutes \[equivalent to 3 minutes "on" time\].

    Treatment: Schwind AMARIS excimer laser and Corneal collagen crosslinking epi-off accelerated

  • PTK + CXLExisting treatment, for comparison

    Epithelial removal by PTK using Schwind AMARIS, followed by accelerated epi-off CXL. Intensity: 30 mW/cm² (pulsed 1 s on / 1 s off; 50% duty cycle). Total energy (fluence): 5.4 J/cm². Total time (elapsed): 6 minutes \[equivalent to 3 minutes "on" time\].

    Treatment: Schwind AMARIS excimer laser and Corneal collagen crosslinking epi-off accelerated

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Corneal Wavefront Guided PRK Combined With Epi-off Corneal Cross-Linking Versus Epi-off Corneal Cross-Linking With PTK Epithelial Removal in Keratoconus: A Randomized Clinical Trial
Plain-language title
Laser surface treatment combined with cross-linking for keratoconus, compared with cross-linking aloneGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
28 January 2026